CCBIO-seminar 29. januar 2026 – Katrin Kleinmanns

Foreleser: Katrin Kleinmanns, forsker i CCBIO i Bjørges og Mc Cormacks grupper. Katrin vil holde sitt innlegg fra da hun nylig mottok Onkologisk Forums Ung Forsker-pris. Les om det i denne HealthTalk-artikkelen.

Tittel: Translational PDX models as a platform to advance therapy in ovarian cancer

Vert: Professor Line Bjørge

Sted: Auditorium 4, BB-bygget

Når: 29. januar 2026 kl. 14.30–15.30

Påmelding er ikke nødvendig. Merk derimot at hvis du er student og trenger studiepoeng for oppmøte, må du melde deg opp i Studentweb for dette emnet for gjeldende semester.

Sammendrag:

Despite advances in surgery and first-line targeted therapies, patients diagnosed with the most aggressive and prevalent subtype of epithelial ovarian cancer, high-grade serous ovarian carcinoma (HGSC), experience poor prognosis, with five-year survival rates around 50% and recurrence rates remaining staggeringly high at 75%. Advancing treatment for these patients requires a paradigm shift that integrates novel therapeutic, optimizes cytoreductive surgery, and incorporates molecular tumor profiling. A major obstacle in improving treatment for this group is the lack of biologically relevant models that accurately reflect tumor heterogeneity, the tumor microenvironment (TME), and mechanisms of therapy resistance. This gap has strongly motivated my work. In this talk, I will provide a brief overview of:

• Establishing patient-derived xenograft (PDX) models to preserve patient heterogeneity and the TME
• Identifying CD24 as a biomarker for non-invasive fluorescence imaging and image-guided surgery
• Developing humanized models through co-engraftment of human tumors and immune cells to evaluate immunotherapies in HGSC
• Targeting chemoresistant cancer cells using personalized treatment approaches
• Profiling the TME to identify predictive, prognostic, and response biomarkers